EQL PHARMA AB (7JK) — Cash Flow-to-Debt Ratio
EQL PHARMA AB (7JK) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of €13.44 Million could theoretically repay 0% of its total liabilities (€543.76 Million) in one year. See EQL PHARMA AB (7JK) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
EQL PHARMA AB Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for EQL PHARMA AB across 4 annual periods. Also explore how fast is EQL PHARMA AB growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for EQL PHARMA AB (2022–2025)
Year-by-year debt coverage analysis for EQL PHARMA AB. For market capitalisation and broader financial context, see 7JK market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.04x | €-24.65 Million | €587.79 Million | ▲ +28.1% |
| 2024 | -0.06x | €-11.44 Million | €196.03 Million | ▼ -127.7% |
| 2023 | 0.21x | €27.62 Million | €130.94 Million | ▼ -42.4% |
| 2022 | 0.37x | €41.83 Million | €114.26 Million | — |